March 2022

Agefi reports on the start of on-site production

The Swiss daily business newspaper Agefi published an interview with our CEO Daniela Marino following the announcement that CUTISS started onsite denovoSkin production, at its very own GMP facility. This is an exciting milestone for the company, resulting in greater production flexibility and scale-up opportunities. Newsroom Link to Interview

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator

CUTISS achieves full independence in its manufacturing capabilities with onsite facility. Increased agility and capacity in producing denovoSkin for current and future clinical trials and patients on compassionate basis. Successful transfer of technology and departure from Wyss Zurich Translational Center, a joint accelerator created by Hansjörg Wyss together with the University of Zurich and ETH …

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.